CME Grand Rounds for Oncologists,
Surgeons and Urologists

IMER Regional Meeting

Community Oncology Clinical
Debates in Prostate Cancer

Click here to request this program for your organization.
Person requesting form:

Contact name/administrative representative (if different from above):
Organization:
Street address:
City:
State:
Zip:
Contact phone:
Contact fax:
Contact E-mail:
Expected number of
medical oncologists:
Expected number
of urologists:
Expected number of
surgical oncologists:
Expected number of
general surgeons:
Expected number of
PAs and NPs:
Expected total number
of attendees:
Date and time of requested program (1st choice):
Date and time of requested program (2nd choice):
Date and time of requested program (3rd choice):

Thank you. We value your feedback.

Please allow 2 business days for a response from our office.

Target Audience

This activity has been designed to meet the educational needs of community-based medical oncologists and urologists.

Purpose

To educate oncologists and urologists on ongoing debates relating to the optimal management of patients with prostate cancer.

Program Overview

Prostate cancer is a complex disease for which treatment requires a multidisciplinary, multimodality approach. In recent years, several new treatment approaches have been explored. However, because of a dearth of long-term data to support treatment recommendations, several clinical debates exist regarding optimal patient management. Medical oncologists, urologists, and radiation oncologists must understand the available data and must work collaboratively to tailor prostate cancer therapy in order to optimize patient outcomes.

This interdisciplinary academic- and community-based grand rounds series will focus on the most pivotal ongoing debates relating to the management of prostate cancer. Thought leader faculty will provide an overview of clinical debates, followed by one or more case studies to stimulate interdisciplinary discussion.

Learning Objectives

Upon completion of this program, participants should be better able to:

  • Describe how treatment options differ for high- versus low-risk disease
  • Identify the optimal timing of chemotherapy for patients with hormone-refractory disease
  • Describe optimal management strategies for secondary hormonal therapies
  • Outline therapy options for treating hormone-refractory metastatic disease following chemotherapy failure
  • Outline an approach to medical/radiology/urology collaboration to achieve optimal patient outcomes

Program Agenda
  • Program Overview (5 mins)
  • Overview of Interdisciplinary Debates (25 mins)
    • Case study: How is high- versus low-risk disease defined? Which patients are candidates for surgery, radiation, hormonal therapy, or active surveillance?
    • What is the optimal timing of androgen-deprivation therapy in patients who elect watchful waiting without local therapy?
    • Case study: What is the definition of hormone-refractory disease? When should chemotherapy be initiated for patients with hormone-refractory prostate cancer?
    • How to best manage secondary hormonal therapies?
    • How to treat hormone-refractory disease following chemotherapy failure?
  • Interdisciplinary Discussion of Debates and Case Studies (30 mins)
Jointly sponsored by:

IMER
Postgraduate Institute for Medicine

This activity is supported by an independent educational grant from sanofi-aventis U.S.

Select Other Community Oncology Clinical Debates


Additional CME Meetings on This Topic
{date} {city} {speaker}

{icon}
{location}

Faculty

MEDICAL ONCOLOGIST
Oliver A. Sartor, MD
(Co-Chairman)
Tulane Medical School

Joshi J. Alumkal, MD
Oregon Health & Science University

Tomasz M. Beer, MD
 Oregon Health & Science University

Charles G. Drake, MD, PhD
The Sidney Kimmel
Comprehensive Cancer Center
at Johns Hopkins

Robert Dreicer, MD, FACP
Cleveland Clinic

L. Michael Glodé, MD, FACP
University of Colorado Cancer Center

Celestia S. Higano, MD, FACP
 University of Washington
School of Medicine

Judd W. Moul, MD, FACS
Duke University Medical Center

SURGICAL ONCOLOGIST
Leonard G. Gomella, MD, FACS
(Co-Chairman)
Thomas Jefferson University

William K. Oh, MD
Dana-Farber Cancer Institute

Daniel P. Petrylak, MD
Columbia University Medical Center

Joel Picus, MD
Washington University
School of Medicine

Charles J. Ryan, MD
UCSF Medical Center

Susan F. Slovin, MD, PhD, FACP
Memorial Sloan-Kettering Cancer Center

Andrew J. Stephenson, MD
Cleveland Clinic Foundation

Mary-Ellen Taplin, MD
Dana-Farber Cancer Institute

 
Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and Institute for Medical Education & Research (IMER). PIM is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.